Our Focus
The West Virginia Chapter of the National Bleeding Disorders Foundation, WVNBDF, provides education, support, awareness, and advocacy for the bleeding disorder community.
We are the leading resource for West Virginians affected by bleeding disorders. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Our Mission ... Into Action
-
We provide mission-focused experiences through education, support, community connections, and fun for those affected by bleeding disorders.
-
We provide year-round events and fundraisers to spread awareness, educate, and generate crucial resources in support of our mission. Hope to see you at our next event!
-
AdvocacyWe fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
News Articles
Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation is focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community. We carry out our work with volunteer expert advisors on our scientific advisory group, investment committee and board of directors. Today we spotlight our investment committee, our process for determining what is presented to this committee and the criteria used in making NBDF’s Pathway to Cures investments.
NBDF is pleased to inform U.S.-based clinicians and other interested individuals of a new series of virtual educational opportunities organized by our friends at the Irish Haemophilia Society (IHS). The IHS is hosting a series of clinical webinars on key topics developed for healthcare providers practicing in the global bleeding disorders community. The six webinars will be held on Zoom during the months of October, November, and December.
Star Therapeutics recently announced new financing (totaling $125 million) that will help the San Francisco-based biotechnology company continue to develop their investigational von Willebrand disease therapy VGA039. The U.S. Food and Drug Administration granted Fast Track designation to the experimental subcutaneous von Willebrand disease therapy (VWD) in January 2025.
Advertisement
Click to learn more.
